Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$22.3B
82M shares
52-week range
$241.81 – $293.72
74% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NYSE
CS
Borrow rate
0.27%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.33B | $11.55B | $13.98B | $13.14B | $11.86B | $12.16B | $13.01B | $13.95B |
| Cost of revenue | $8.16B | $8.30B | $9.03B | $8.14B | $8.15B | $8.80B | $9.38B | $10.22B |
| Gross profit | $3.18B | $3.25B | $4.95B | $4.99B | $3.71B | $3.36B | $3.62B | $3.73B |
| Gross margin | 28.0% | 28.1% | 35.4% | 38.0% | 31.3% | 27.7% | 27.9% | 26.8% |
| R&D | $0 | $0 | $0 | $0 | $0 | $2.0M | $0 | $0 |
| Operating income | $1.33B | $1.33B | $2.45B | $3.05B | $1.44B | $725.6M | $1.09B | $1.52B |
| EBITDA | $2.06B | $2.12B | $3.25B | $3.68B | $1.95B | $1.35B | $1.81B | $2.01B |
| Net income | $883.7M | $823.8M | $1.56B | $2.38B | $1.28B | $418.0M | $746.0M | $876.5M |
| Net margin | 7.8% | 7.1% | 11.1% | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% |
| EPS (diluted) | 8.61 | 8.36 | 15.88 | 24.38 | 13.96 | 4.77 | 8.84 | 10.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14.7B | $18.01 | $17.71–$18.34 | 9 |
| 2027 | $15.4B | $19.49 | $18.62–$20.00 | 12 |
| 2028 | $16.1B | $21.18 | $19.05–$23.98 | 8 |
| 2029 | $17.1B | $23.58 | $23.31–$23.88 | 6 |
Forward consensus · source: Financial Modeling Prep
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
www.labcorp.comNo one on the platform currently holds LH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 59,205 | $13.2M |
| Bridgewater Associatesas of 2026-03-31 | 11,184 | $3.0M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.7200 | 2026-06-11 |
| 2026-02-27 | $0.7200 | 2026-03-12 |
| 2025-11-26 | $0.7200 | 2025-12-11 |
| 2025-08-28 | $0.7200 | 2025-09-11 |
| 2025-05-29 | $0.7200 | 2025-06-11 |
| 2025-02-27 | $0.7200 | 2025-03-12 |
| 2024-11-26 | $0.7200 | 2024-12-13 |
| 2024-08-29 | $0.7200 | 2024-09-13 |
| 2024-05-24 | $0.7200 | 2024-06-12 |
| 2024-02-26 | $0.7200 | 2024-03-13 |
No one on the platform has traded LH yet.
| $27.4B |
| — |
| INCYIncyte Corporation | $114.66 | +0.80% | $22.9B | — |
| STESTERIS plc | $213.24 | -1.13% | $20.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-11-07 |
| $0.7200 |
| 2023-12-12 |
| 2023-08-07 | $0.7200 | 2023-09-08 |
| Execution date | Ratio |
|---|---|
| 2023-07-03 | 1164-for-1000 |
Trading at 32.3× earnings vs its 24.4× historical median P/E.
Fair value ≈ $211.53 · price $280.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $18.59 – $22.96 Target Zone: $29.73 – $36.34 Potential Upside: 51% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $17.25 – $21.32 Target Zone: $29.41 – $35.95 Potential Upside: 61% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$AMN came up on my Reversed DCF screener as pricing in most FCF decline.. potentially lots of value here.. $LH $GH $BTSG $DVA
View on StockTwits ↗$LH Current Stock Price: $258.04 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.71 Exit: $4.20 ROI: 55% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$LH Current Stock Price: $256.92 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.65 Exit: $4.73 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$LH Price: $257.48 (+0.13%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.23% RSI: 37.3 | Momentum: Moderate Volume: -26.1% vs avg Volatility: 1.54% Support: $248.59 | Resistance: $279.71 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗$LH Share Price: $252.43 Contract Selected: Nov 20, 2026 $250 Calls Buy Zone: $19.38 – $23.94 Target Zone: $31.22 – $38.15 Potential Upside: 52% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$LH Based on 10 Wall Street analysts offering 12 month price targets for Labcorp Holdings in the last 3 months the average price target is $309.63 with a high forecast of $334.00 and a low forecast of $290.00. The average price target represents a nice gain. Tune out the FUD. ✅📶
View on StockTwits ↗@StocktwitsEarnings Great, now give me a raise $LH 😭🤣
View on StockTwits ↗$LH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.37 up 32.68% YoY • Reported revenue of $3.54B up 5.75% YoY • Labcorp raised full-year 2026 enterprise revenue guidance to 5.0% to 6.1% and adjusted EPS guidance to a range of $17.70 to $18.35, reflecting an increase of 13 cents at the midpoint.
View on StockTwits ↗$LH announced the launch of its FDA‑cleared Fentanyl Urine Visual Test, the first rapid fentanyl test of its kind manufactured in the U.S. It delivers results in ~10 minutes for use in ERs, hospitals and clinics—critical when you’re triaging suspected exposure/overdose. https://prismmarketview.com/labcorp-unveils-10-minute-fda-cleared-fentanyl-test-for-emergency-settings/
View on StockTwits ↗$LH up 10.2% in the past year, but are macro headwinds a threat? ⚠️ 🔍 Strategic test expansion in neurology, oncology, & autoimmune disease 🚀 🌍 Currency fluctuations & geopolitical tensions could dent overseas revenues Discover the full growth vs. risk analysis here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-body-35856&ADID=SYND_STOCKTWITS_TWEET_2_2878452_BODY_35856
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.